Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS582949 (PS540446) 是一种有效的选择性 p38 丝裂原活化蛋白激酶(p38 MAPK) 抑制剂,IC50 为 13 nM,抑制 p38 激酶活性和 p38 活化。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 768 | 现货 | ||
2 mg | ¥ 1,180 | 现货 | ||
5 mg | ¥ 1,980 | 现货 | ||
10 mg | ¥ 3,060 | 现货 | ||
25 mg | ¥ 4,930 | 现货 | ||
50 mg | ¥ 7,170 | 现货 | ||
100 mg | ¥ 9,670 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,150 | 现货 |
产品描述 | BMS-582949 is a potent and selective p38 mitogen-activated protein kinase (p38 MAPK) inhibitor with IC50 of 13 nM, inhibiting both p38 kinase activity and activation of p38. |
靶点活性 | p38 MAPK (cell-free assay):13 nM |
体外活性 | BMS-582949 is found to inhibit p38 activation in cells, as measured by phosphorylation of p38. BMS-582949 treatment of cells in which p38 has been activated by LPS rapidly reversed p38 activation as shown by loss of phosphorylation of p38. BMS-582949 is therefore a dual action p38 kinase inhibitor, inhibiting both p38 kinase activity and p38 activation in cells. BMS-582949 binding to p38a results in a conformational change of the activation loop which is phosphorylated by upstream kinases, therefore it inhibits phosphorylation of p38 by upstream MKK by inducing a less accessible conformation of the activation loop[2]. |
体内活性 | The mouse clearance rate for BMS-582949 is 4.4 mL/min/kg. And at an oral dose of 10 mg/kg, the mouse AUC0-8 h for BMS-582949 is 75.5 μM?h. BMS-582949 exhibited oral bioavailability values of 90% and 60% in mice and rats, respectively[1]. |
激酶实验 | Autophosphorylation activity is measured by adding of 32P-γ ATP. Endonuclease activity is measured by the adding of radiolabeled HAC1 508-nt RNA substrate synthesized in vitro using α32P-UTP. Mix STF083010 with recombinant hIRE1 protein, radiolabeled HAC1 508 nt RNA, and appropriate buffers to incubate. Kinase activity is quantitated by polyacrylamide gel electrophoresis. RNAsecleavage products are quantitated by 32P-γATP or 32P-UTP autoradiography. |
别名 | BMS 582949, PS540446, BMS-582949 |
分子量 | 406.48 |
分子式 | C22H26N6O2 |
CAS No. | 623152-17-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 75 mg/mL (184.5 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4601 mL | 12.3007 mL | 24.6015 mL | 61.5036 mL |
5 mM | 0.492 mL | 2.4601 mL | 4.9203 mL | 12.3007 mL | |
10 mM | 0.246 mL | 1.2301 mL | 2.4601 mL | 6.1504 mL | |
20 mM | 0.123 mL | 0.615 mL | 1.2301 mL | 3.0752 mL | |
50 mM | 0.0492 mL | 0.246 mL | 0.492 mL | 1.2301 mL | |
100 mM | 0.0246 mL | 0.123 mL | 0.246 mL | 0.615 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BMS582949 623152-17-0 MAPK p38 MAPK PS-540446 BMS 582949 PS 540446 PS540446 BMS-582949 Inhibitor inhibitor inhibit